Form 4: Heartflow CMO Granted Significant Equity Awards

Heartflow's Chief Medical Officer, Campbell Rogers, was granted 21,052 Restricted Stock Units and 110,629 stock options, vesting over several years.

Summary

• Chief Medical Officer Campbell Rogers received 21,052 Restricted Stock Units (RSUs) and 110,629 stock options.
• The RSUs have a vesting commencement date of August 7, 2025, with 1/16th vesting on each quarterly anniversary, contingent on continued service.
• The stock options have an exercise price of $19.00, a vesting commencement date of August 7, 2025, and vest 1/48th on each monthly anniversary, also contingent on continued service.
• The stock options are set to expire on August 7, 2035.
• Following these transactions, Campbell Rogers directly holds 21,052 common shares and 110,629 stock options.
• Indirect beneficial ownership includes 22,615 shares via the Campbell Rogers 2019 Irrevocable Trust, 46,159 shares via the CR Asset Protection Trust of 2023, 26,012 shares via Spouse's Trust, and 50,754 shares via The Campbell Rogers Revocable Trust.

Sentiment

Score: 7

Explanation: The grant of significant equity awards to a key executive is generally a positive signal for retention and alignment of interests, indicating confidence in the executive's continued contribution and the company's future prospects. No negative information was presented.

Positives

• The grant of equity awards (RSUs and stock options) aligns the Chief Medical Officer's interests with long-term shareholder value.
• The multi-year vesting schedules for both RSUs (quarterly over 4 years) and stock options (monthly over 4 years) serve as a strong retention mechanism for key management.

Negatives

• No direct negatives identified in this Form 4 filing, as it primarily reports an equity grant.

Risks

• The value of the granted equity awards is subject to the future performance of Heartflow's stock price.
• Vesting of awards is contingent on continued service, meaning unvested portions could be forfeited if employment ceases.

Future Outlook

The equity grants with multi-year vesting schedules indicate an expectation of continued service from the Chief Medical Officer and a long-term strategic alignment with the company's future performance.

Industry Context

Equity grants to key executives like the Chief Medical Officer are a standard practice in the biotechnology and medical device industry to attract, retain, and incentivize top talent, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The structure of RSU and stock option grants with multi-year vesting is consistent with typical executive compensation packages in the healthcare technology sector, similar to practices observed at companies like Intuitive Surgical or Medtronic for their senior leadership.
• The exercise price of $19.00 for the options would typically be set at or above the market price on the grant date, a common practice for incentive stock options.

Stakeholder Impact

• Shareholders: The grants align management's interests with shareholder value creation, potentially leading to better long-term performance. Dilution from option exercise is a consideration, but it is a standard part of compensation.
• Employees: May signal stability in leadership and a commitment to retaining key talent.
• Management: Provides significant long-term incentive and compensation.

Next Steps

• Continued service by the Chief Medical Officer to ensure vesting of the equity awards.
• Future SEC filings will report any subsequent changes in beneficial ownership for Campbell Rogers.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a key executive, which is a standard part of compensation and retention strategy. It does not provide new information that would fundamentally alter the investment thesis for Heartflow, Inc. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Heartflow, HTFL, Campbell Rogers, Chief Medical Officer, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, Form 4